建議您使用以下瀏覽器觀看合一網站,
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?
- 開啟新分頁(紅色框)
- 於搜尋框中打入Edge(紅色框),並按搜尋(藍色框)
- 點擊【立即啟動】(藍框處)打開 Microsoft Edge
Title
S.C. injection formulation of FB825 has been agreed by US FDA to proceed with Phase 2 clinical trial to treat moderate-to-severe atopic dermatitis.
Announcement the Company's board of directors meeting date of the First Quarter of 2024 Consolidated Financial Reports
Oneness Biotech Co., Ltd. receives a Japanese patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).
News-Microbio and Oneness Ranked among Top 5% in the 10th Corporate Governance Evaluation
Subcutaneous injection formulation of FB825 to treat moderate-to-severe atopic dermatitis was greenlighted by TFDA to proceed with a Ph2 study
Submission of a phase II clinical trial protocol to Taiwan FDA for subcutaneous injection formulation of FB825 in patients with moderate-to-severe atopic dermatitis
Oneness announces the information about the investor's conference of 2024 Q1.
Oneness Biotech Co., Ltd. receives a Saudi Arabian patent titled "TOPICAL FORMULATION FOR PROMOTING WOUND HEALING" on Fespixon cream (Research code: ON101).
Announce the change of the internal audit officer.
The board of directors of the Company approved removal of the noncompete clause for managers.
Annouce the change of the spokesperson.
Annouce the change of the general manager.
Oneness Board of Directors resolved to convene the Annual Shareholders' Meeting of 2024.
The Board of Directors resolved to the new common share issuance through the increase of capital by capitalization of capital surplus
The Board of Directors resolved to distribute dividends.
建議您使用以下瀏覽器觀看合一網站,
以獲得最佳瀏覽效果。
如何使用IE找到Microsoft Edge?